NCT04626024View on ClinicalTrials.gov

Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 22, 2020

Primary Completion Date

November 15, 2025

Study Completion Date

November 15, 2025

Conditions
Chronic Myeloid LeukemiaChronic Myeloid Leukemia, BCR/ABL-Positive, in RemissionChronic Myeloid Leukemia in Remission
Interventions
OTHER

Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal

Stop taking TKI medication

DRUG

Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation

Re-start TKI medication

Trial Locations (4)

77030

RECRUITING

Baylor College of Medicine- McNair Campus, Houston

RECRUITING

Ben Taub General Hospital, Houston

RECRUITING

CHI St. Luke's Health Baylor College of Medicine Medical Center, Houston

77054

RECRUITING

Harris Health System- Smith Clinic, Houston

All Listed Sponsors
lead

Baylor College of Medicine

OTHER